XBiotech Provides Update on XilonixTM Phase III Programs in US and EU
XBiotech announced the IDMC for the XCITE Phase III clinical study of Xilonix™ for the treatment of colorectal cancer, recently recommended study continuation without any amendment to the study design. The DMC convened as scheduled, subsequent to the enrollment of 400 patients into the study. July 22, 2016